Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...

Jaypirca and Omvoh should also contribute meaningfully through the end of the decade. In other words, Eli Lilly's revenue should continue growing at a good clip. The midpoint of the company's ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Omvoh and Kisunla, approvals of new indications for existing Lilly medicines, launches of Mounjaro in additional worldwide markets, among other factors. Given Eli Lilly and Company (NYSE ...

In addition to its metabolic disease portfolio, Eli Lilly is also making strides in other therapeutic areas. The recent approval of Omvoh for Crohn's disease marks the company's entry into the ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two ...

(You can read the full research report on Apple here >>>) Eli Lilly's shares ... In the past two years, Lilly has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca.